Neutropenia News - LARVOL Sigma

Neutropenia	Welcome, Profile Billing Logout

«1 2...16 17 18 19 202122 23 24 25 26...645 646 »

|||||||||| OP-35: Does a tool designed to measure potentially preventable chemotherapy toxicities do so effectively? (Hall A - Posters and Exhibits; Poster Bd #: 291) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2323;
The qualifying diagnosis list may need to be tailored to exclude non-preventable admissions. This would improve the metric's specificity and validity as measure of care-quality.

|||||||||| SHR-1826 / Jiangsu Hengrui Pharma
Phase 1 study of SHR-1826, a c-MET (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2271;
P1

|||||||||| ABBV-706 / AbbVie
Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6) (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2270;
P1
This would improve the metric's specificity and validity as measure of care-quality. ABBV-706 showed preliminary efficacy in several high-grade NENs with a high unmet need, supporting its further development in specific subtypes.

|||||||||| doxorubicin hydrochloride / Generic mfg.
A phase Ib/II trial of radiotherapy combined with doxorubicin and PD-1 antibody for localized high-risk limbs and trunk soft tissue sarcomas. (Hall A - Posters and Exhibits; Poster Bd #: 51) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2097;
P1/2
Participants will receive RT (BED = 50-60 Gy), combined with DOXO and PD-1 antibody (Sintilimab, SIN 200 mg, Day 1) every three weeks for four cycles prior to surgery. In Phase Ib (3+3 design), patients will receive Pegylated liposomal doxorubicin (PLD, 37.5 mg/m

|||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Epidaza (chidamide) / Chipscreen
A phase II, multicenter trial of the combination of chidamide and toripalimab in patients with advanced soft tissue sarcoma: Efficacy updates. (Hall A - Posters and Exhibits; Poster Bd #: 43) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2096;
P2
Chidamide with Toripalimab every 21 days was well tolerated and showed promising efficacy in patients with advanced STS. The exploratory biomarker study is ongoing.

|||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Phase Ib/II study of fluzoparib in combination with dalpiciclib in patients with locally advanced or metastatic sarcoma. (Hall A - Posters and Exhibits; Poster Bd #: 16) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2059;
P2
Part 2 to evaluate safety and efficacy is currently recruiting pts. TRAEs with an incidence of ?30% and any grade ?3 TRAEs.

|||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
ImmunoSarc2 (Cohort 7a): A Spanish Sarcoma Group (GEIS) phase Ib trial of epirubicin and ifosfamide plus nivolumab in first line of advanced undifferentiated pleomorphic sarcoma (UPS). (S504) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2035;
P1/2
Epirubicin 60 mg/m2/d d1-2 plus Ifosfamide 3 g/m2/d d1-3 plus NIV 360 mg on d3 Q3W, followed by 1 year of NIV is a feasible and manageable scheme that exhibits relevant activity as an upfront line in advanced UPS patients. A phase II/III trial is designed aiming to confirm the advantage of chemo-immunotherapy over chemotherapy alone in this context.

|||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713). (S504) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2034;
P2
A phase II/III trial is designed aiming to confirm the advantage of chemo-immunotherapy over chemotherapy alone in this context. Taken together, the results indicate that the combination regimen of nivolumab with metronomic gemcitabine, doxorubicin and docetaxel may have synergistic activity and is an effective treatment for advanced leiomyosarcoma and liposarcoma with manageable toxicity.

|||||||||| C019199 / Fujian Haixi New Pharmaceutical
Phase Ib trial of C019199, an oral TME modulator targeting CSF-1R/DDRs/VEGFR2, in relapsed or refractory osteosarcoma. (S504) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2033;
P
Combined with the encouraging tolerability and safety data, it suggests that C019199 has the potential to effectively benefit survival and improve quality of life for patients of this indication. The Phase Ib study is concluding, and a Phase III study is planned.

|||||||||| Verzenio (abemaciclib) / Eli Lilly
A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with HIV-associated and HIV-negative Kaposi sarcoma. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2026;
P1/2
Abema is a novel therapeutic option in KS, with notable activity among pts with previously untreated KS. Adverse events were managed with dose reduction and supportive measures.

|||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator's choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2020;
P2/3
This suggests that a biomarker may be needed before there is further exploration of PARP inhibitor-based regimens in uLMS. Overall survival and analysis of tissue-based biomarkers will be presented.

|||||||||| Impact of protein-energy malnutrition on inpatient mortality, healthcare cost and clinical outcomes among patients with head and neck cancer. (Hall A - Posters and Exhibits; Poster Bd #: 403) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1998;
Prospective trials evaluating strategies to improve PEM, and provide adequate nutritional support are essential to enhance clinical outcomes, reduce mortality and decrease healthcare costs. Effect of PEM on clinical and healthcare outcomes among hospitalized patients with HNC.

|||||||||| Impact of palliative chemotherapy in hospitalized patients with advanced solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 489) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1991;
PC in hospitalized cancer patients with ECOG-PS > 2 was associated with shorter survival, longer hospital stays, and higher rates of early mortality. These findings emphasize the importance of careful patient selection and the need for further research to optimize care strategies in this population.

|||||||||| MYTX-011 / Mythic Therap
MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study. (Hall A - Posters and Exhibits; Poster Bd #: 93) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1760;
P1
Preliminary anti-tumor activity suggests MYTX-011 can potentially benefit a wide range of cMET-expressing NSCLC pts. Dose expansion is currently ongoing as of January 2025.

|||||||||| Avastin (bevacizumab) / Roche, Ivesa (firmonertinib) / Allist, ArriVent
High-dose furmonertinib combined with bevacizumab and pemetrexed in non-small cell lung cancer patients with EGFR mutations and leptomeningeal metastasis: A prospective real-world study. (Hall A - Posters and Exhibits; Poster Bd #: 89) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1756;
P=N/A
Dose expansion is currently ongoing as of January 2025. High-dose furmonertinib combined with bevacizumab and pemetrexed demonstrates remarkable clinical efficacy and tolerable safety in NSCLC patients with EGFR mutations and LM.

|||||||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). (Hall A - Posters and Exhibits; Poster Bd #: 79) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1749;
P3
Consistent with the final analysis, SG showed a numerical improvement in OS vs docetaxel. Long-term safety showed SG is well tolerated, consistent with minimal increase in AE rates since prior report and an improved safety profile over docetaxel, despite longer treatment exposure.

|||||||||| Tecentriq (atezolizumab) / Roche
Phase 2 study of atezolizumab with carboplatin plus pemetrexed followed by maintenance atezolizumab with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: CJLSG1902. (Hall A - Posters and Exhibits; Poster Bd #: 60) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1717;
Atezolizumab with carboplatin plus pemetrexed followed by maintenance atezolizumab with pemetrexed showed favorable efficacy and the safety profile was manageable. This combination therapy is an encouraging option as a first-line treatment strategy for elderly patients with metastatic non-squamous NSCLC.

|||||||||| telisotuzumab adizutecan (ABBV-400) / AbbVie
Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein (Arie Crown Theater) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1659;
P1
aConfirmed responses. P, probability.

|||||||||| Jiataile (sacituzumab tirumotecan) / Merck (MSD)
Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. (Arie Crown Theater) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1648;
P2
Sac-TMT demonstrated improved ORR, PFS and OS compared to docetaxel, with manageable safety profile in pts with previously treated advanced EGFRm NSCLC. These results highlight significant survival benefits and suggest that sac-TMT could emerge as a new standard of care for this population.

|||||||||| LB2102 / Novartis
Safety, tolerability, and preliminary efficacy results of a phase 1 study of LB2102, a dnTGF?RII armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). (Hall A - Posters and Exhibits; Poster Bd #: 225) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1601;
P1
There appears to be a dose-dependent efficacy signal observed at higher doses with responses correlating to CAR-T expansion, although the data is limited. Given no DLTs and preliminary efficacy signal up to DL3, further exploration of higher dose levels is warranted.

|||||||||| HTMC0435 / Shanghai Huilun
Efficacy and safety of HTMC0435 combination with temozolomide in relapsed extensive-stage small-cell lung cancer (ES-SCLC): A phase Ib/II study. (Hall A - Posters and Exhibits; Poster Bd #: 218) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1584;
P1b/2
Clinical trial information: NCT05728619. Research Sponsor: Shanghai Yidian Pharma.

|||||||||| obrixtamig (BI 764532) / Boehringer Ingelheim
DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results. (Hall A - Posters and Exhibits; Poster Bd #: 215) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1559;
P1
AE frequency and severity reported for the combination were consistent with the expected safety findings for obrixtamig and topotecan as monotherapy. Preliminary efficacy data for the combination are encouraging and indicate an improvement on top of topotecan monotherapy.

|||||||||| Tecentriq (atezolizumab) / Roche
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. (Arie Crown Theater) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1532;
P3
Lurbi + atezo was generally well tolerated, with no new or unexpected safety signals. IMforte is the first global Phase 3 study to show PFS and OS improvement with 1L maintenance tx for ES-SCLC and supports maintenance lurbi + atezo as a new option for pts with this aggressive disease.

|||||||||| Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304. (Arie Crown Theater) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1529;
P3
The DeLLphi-304 trial showed tarlatamab significantly improved OS, PFS, and PROs, with a favorable safety and tolerability profile compared to CTx in pts with SCLC that progressed on or after initial platinum-based CTx, defining a new standard of care for these patients. Clinical Trial Information: NCT05740566; Legal entity responsible: Amgen Inc.; Funding: Amgen Inc.; Editorial acknowledgement: Medical writing support for the development of this abstract was provided by Sukanya Raghuraman, PhD, of Cactus Life Sciences, part of Cactus Communications, and was funded by Amgen Inc.

|||||||||| Tecentriq (atezolizumab) / Roche
Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145). (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1522;
P1/2, P3
The associated safety profile is manageable. The regimen is being evaluated in a phase III trial in the maintenance setting (IMforte trial NCT05091567).

|||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety results. (S100a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1505;
P2
SHR-A1811 demonstrated promising efficacy in both HER2-positive and HER2-low advanced salivary gland cancers, achieving high ORRs and DCRs with an acceptable toxicity profile. Baseline characteristics.

|||||||||| alrizomadlin (APG-115) / Ascentage Pharma
A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors. (Hall A - Posters and Exhibits; Poster Bd #: 510) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1494;
P1/2
Alrizomadlin monotherapy showed promising antitumor activity in pts with advanced ACC or MPNST. Alrizomadlin combined with toripalimab was also well tolerated, showing antitumor activity in MPNST, BTC, and LPS and an acceptable safety profile (NCT04785196).

|||||||||| PF-08046054 / Pfizer
Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC. (Hall A - Posters and Exhibits; Poster Bd #: 441) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1475;
P1
Early encouraging objective responses were observed in half of the patients treated, including 21.4% with a CR. Enrollment in multiple combination expansion cohorts in PD-L1 expressing tumors is ongoing.

|||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Induction pembrolizumab plus cisplatin and 5-FU chemotherapy followed by chemoradiotherapy in locally advanced squamous cell cancer of oropharynx, hypopharynx or larynx: Results of multicenter prospective phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 478) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1457;
P2
The study demonstrated promising ORR, progression-free survival rate and acceptable safety profile of induction therapy with pembrolizumab, cisplatin and 5-FU in head and neck cancer. High response rate to induction therapy was associated with a high number of CRT completion.

|||||||||| Erbitux (cetuximab) / Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): 1-year outcomes from the phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 438) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1449;
P2
Further evaluation including a phase III study is warranted. Demographics and baseline characteristics.

|||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, TQB2618 / Sino Biopharm
Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study. (Hall A - Posters and Exhibits; Poster Bd #: 439) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1431;
P2
Demographics and baseline characteristics. TQB2618 and penpulimab were administered intravenously at doses of 1200 mg and 200 mg, respectively, on the first day of a 21-day cycle until disease progression or unacceptable toxicity while gemcitabine (1000 mg/m2, d1&8) and cisplatin (75mg/m2, d1) were given intravenously for the first 4

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
Two cycles of neoadjuvant therapy with low-dose radiotherapy, PD-1 inhibitor tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): A phase II, open-label, single-arm trial. (Hall A - Posters and Exhibits; Poster Bd #: 447) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1421;
P2
Neoadjuvant LDR combined with tislelizumab, albumin-bound paclitaxel, and cisplatin resulted in an impressive pCR rate and demonstrated promising efficacy with manageable toxicity in patients with resectable LA HNSCC. Long-term survival data are still follow-up.

|||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial. (Hall A - Posters and Exhibits; Poster Bd #: 448) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1411;
P2
Induction chemo-immunotherapy offered the chance of reRT for high-risk rNPC patients and improved their overall survival with acceptable toxicities. Basic information.

|||||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg.
Which systemic regimen to choose in cisplatin-ineligible patients with concurrent radiation therapy for head and neck cancers: carboplatin/5-flurouracil or carboplatin/paclitaxel? (Hall A - Posters and Exhibits; Poster Bd #: 498) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1406;
Basic information. Concurrent chemoRT with CP offers similar efficacy compared to CF, with less toxicity and can be established as to go chemotherapy regimen with radiation therapy in patients who are ineligible for Cisplatin.

|||||||||| PRGN-2009 / Precigen
Phase II trial of neoadjuvant chemotherapy (NAC) docetaxel-cisplatin alone (DC) or with anti-human papillomavirus (HPV) gene therapy PRGN-2009 (DCP) followed by surgery in patients (pts) with newly diagnosed HPV-associated oropharyngeal cancer (HPV-OPC). (Hall A - Posters and Exhibits; Poster Bd #: 521a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1404;
P2
8 of 60 pts planned have been enrolled. Clinical trial registry: NCT06223568.

|||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Phase 2 open-label study of brentuximab vedotin (BV) + pembrolizumab (pembro) in patients (pts) with treatment (tx)-naive metastatic head and neck squamous cell carcinoma (HNSCC). (E450a) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1395;
P2
Biomarker analyses support the hypothesized immunomodulatory mechanism of action of BV + pembro. These encouraging data are consistent with prior findings in PD-1

|||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, Talzenna (talazoparib) / Pfizer
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial. (Hall A - Posters and Exhibits; Poster Bd #: 246) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1368;
P3
At extended follow-up, initial treatment with TALA + ENZA resulted in clinically meaningful improvement in OS, rPFS by BICR, and secondary efficacy endpoints vs PBO + ENZA in unselected pts with mCRPC in the TALAPRO-2 China cohort. No new safety signals were identified; QoL was maintained.

|||||||||| bleomycin / Generic mfg.
Risk factors and causes of early death among patients with germ cell testis tumors (GCTs): An international collaborative study supported by the Global Society of Rare Genitourinary Tumors. (Hall A - Posters and Exhibits; Poster Bd #: 229) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1338;
The proportion of patients with early death is low, but this group presents significant clinical challenges. Among advanced GCTs, high beta-HCG levels, liver metastases, massive lung involvement, poor ECOG and/or need of intensive care are associated with a higher risk of early death and need targeted intervention to improve their therapeutic outcomes.

|||||||||| peposertib (M3814) / EMD Serono, Bavencio (avelumab) / EMD Serono, Xofigo (radium Ra-223 dichloride) / Bayer
A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results. (Hall A - Posters and Exhibits; Poster Bd #: 268) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1321;
P1/2
The triplet combination showed the most promising results at this early evaluation. We continue to accrue in the randomized Phase II portion of the trial.

|||||||||| Talzenna (talazoparib) / Pfizer, Tazverik (tazemetostat) / Ipsen
A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC). (Hall A - Posters and Exhibits; Poster Bd #: 241) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1311;
P1
Companion blood and tissue-based correlative studies to characterize pharmacodynamic biomarkers of combined PARP+EZH2 inhibition and biomarkers of response and resistance are ongoing. (NCT04846478)

|||||||||| carboplatin / Generic mfg.
Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V) (Hall A - Posters and Exhibits; Poster Bd #: 257) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1309;
P2
Carboplatin was associated with meaningful clinical benefit in mCRPC pts with DDR alterations detected in ctDNA, but not in pts without DDR alterations. Carboplatin warrants further evaluation in mCRPC pts with DDR gene alterations.

|||||||||| zelenectide pevedotin (BT8009) / Bicycle Therap
Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4 (Hall A - Posters and Exhibits; Poster Bd #: 367) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1213;
P1/2, P2/3
Carboplatin warrants further evaluation in mCRPC pts with DDR gene alterations. Zelenectide pevedotin (zele, previously BT8009) is a highly selective Bicycle Toxin Conjugate (BTC) targeting Nectin-4 and conjugated to MMAE, and has shown an objective response rate (ORR) of 45% and a generally tolerable safety profile as monotherapy in previously treated, enfortumab vedotin-na

|||||||||| sasanlimab (PF-06801591) / Pfizer, Trodelvy (sacituzumab govitecan-hziy) / Gilead
A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts: SSANTROP (APRO07-2022). (Hall A - Posters and Exhibits; Poster Bd #: 396) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1155;
With preliminary 3 mo CRR of 68%, the safety analysis identified no unexpected concerns, with severe AEs mainly involving neutropenia and febrile neutropenia. No treatment related toxic deaths occurred.

|||||||||| Erbitux (cetuximab) / Eli Lilly
A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab and mFOLFOX6 plus cetuximab as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer: Primary results of the CAPCET study. (Hall A - Posters and Exhibits; Poster Bd #: 232) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1125;
P2, P3
Biweekly mCapOX plus CET had higher ORR and DCR than mFOLFOX6 plus CET, with signally reduced toxicity. Longer follows-up and a multicenter, open-label, randomized, controlled Phase CAPCET- III study (NCT06616259) will be further validate this innovative regimen.

|||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Real-world efficacy of trifluridine/tipiracil and bevacizumab combination according to baseline prognostic factors: The BeTAS study. (Hall A - Posters and Exhibits; Poster Bd #: 247) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1104;
The ECOG performance status, Tabernero subgroups, and the occurrence of grade 3-4 neutropenia help identify patients who may obtain the maximum benefit from FTD/TPI + BEV treatment. Interestingly, all subgroups analyzed showed a greater benefit compared to the outcomes previously reported for FTD/TPI monotherapy, highlighting the potential of this combination in clinical practice.

|||||||||| Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study. (Hall A - Posters and Exhibits; Poster Bd #: 261) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1094;
P2
Interestingly, all subgroups analyzed showed a greater benefit compared to the outcomes previously reported for FTD/TPI monotherapy, highlighting the potential of this combination in clinical practice. SCRT followed by one cycle of FOLFOX and 7 cycles of FOLFOXIRI showed a promising activity and a feasible safety profile and is therefore worth of further studies especially in the NOM scenario.

|||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Zadaxin (thymalfasin) / SciClone
Safety and efficacy evaluation of neoadjuvant chemoradiotherapy plus thymalfasin and tislelizumab for treating MSS/pMMR locally advanced rectal cancer. (Hall A - Posters and Exhibits; Poster Bd #: 256) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1046;
P2
Neoadjuvant chemoradiotherapy plus thymalfasin and tislelizumab show promising anti-tumour activity in MSS/pMMR LARC patients, with manageable toxicities. This study suggests that such combination could be a promising therapeutic strategy for patients with MSS/pMMR LARC.

|||||||||| azenosertib (ZN-c3) / Zentalis Pharma
Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated BRAF V600E mutant metastatic colorectal cancer (mCRC). (Hall A - Posters and Exhibits; Poster Bd #: 220) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1027;
P1
This study suggests that such combination could be a promising therapeutic strategy for patients with MSS/pMMR LARC. The combination of A+E+C was well tolerated at the MTD and yielded response rates in BRAFi-na

|||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka, IMC001 / Immunofoco
Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer: Initial results of the FIERCE study. (Hall A - Posters and Exhibits; Poster Bd #: 271) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1020;
P1
Short-course filgrastim, or day 29-33 adjustment to DL2, may be needed in last 2 weeks of CRT to prevent dose interruptions. A dose expansion study is being explored as the next step.

|||||||||| Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer. (Hall A - Posters and Exhibits; Poster Bd #: 249) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1018;
Patient characteristics were similar to the SUNLIGHT trial, with high rates of previous antiangiogenic use. A statistically significant and clinically relevant OS benefit was seen with the addition of BEV versus monotherapy consistent with the results of the SUNLIGHT trial.



	Diseases Companies Products Productz Mechanisms of Action Sites